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Background: A small minority of HIV-1-infected individuals show low levels of immune activation and do not
develop immunodeficiency despite high viral loads. Since the accessory viral Nef protein modulates T cell activation
and plays a key role in the pathogenesis of AIDS, we investigated whether specific properties of Nef may be
associated with this highly unusual clinical outcome of HIV-1 infection.
Findings: Comprehensive functional analyses of sequential HIV-1 strains from three viremic long-term non-progressors
(VNP) showed that they encode full-length Nef proteins that are capable of modulating CD4, CD28, CD8ß, MHC-I and
CD74 cell surface expression. Similar to Nef proteins from HIV-1-infected individuals with progressive infection (P-Nefs)
and unlike Nefs from simian immunodeficiency viruses (SIVs) that do not cause chronic immune activation and disease
in their natural simian hosts, VNP-Nefs were generally unable to down-modulate TCR-CD3 cell surface expression to
block T cell activation and apoptosis. On average, VNP-Nefs suppressed NF-AT activation less effectively than P-Nefs
and were slightly less active in enhancing NF-κB activity. Finally, we found that VNP-Nefs increased virion infectivity and
enhanced HIV-1 replication and cytopathicity in primary human cells and in ex vivo infected lymphoid tissues.
Conclusions: Our results show that nef alleles from VNPs and progressors of HIV-1 infection show only modest
differences in established functions. Thus, the lack of chronic immune activation and disease progression in HIV-
1-infected VNPs is apparently not associated with unusual functional properties of the accessory viral Nef protein.
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High viral loads are almost invariably associated with
chronic inflammation and progression to AIDS in HIV-
1-infected individuals. In contrast, some non-human pri-
mates (NHPs) that are naturally infected with SIVs, such
as sooty mangabeys (SMs) or African green monkeys
(AGMs), show low levels of immune activation and do
not develop disease despite high levels of viral replica-
tion [1,2]. Recent data show that a small minority (<1%)
of highly viremic HIV-1-infected individuals, so called
viremic long-term non-progressors (VNP), show a simi-
lar phenotype and remain asymptomatic with low levels
of inflammation and high CD4+ T cell counts [3].* Correspondence: frank.kirchhoff@uni-ulm.de
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stated.It is poorly understood why VNPs can tolerate high
levels of HIV-1 replication. It has been reported, however,
that they show lower levels of proliferating and activated
T cells than progressing individuals with similar viral loads
[3]. Here, we examined whether specific functional prop-
erties of the accessory viral Nef protein may contribute to
the low levels of T cell activation and the lack of disease
progression in VNPs. Nef is a multi-functional manipula-
tor of the viral host cell that facilitates viral immune eva-
sion and is critical for efficient viral replication and disease
progression in HIV-1-infected individuals [4,5]. Primate
lentiviral Nef proteins generally down-modulate CD4 and
MHC-I from the cell surface and enhance viral infectivity
and replication [4,5]. They differ fundamentally, however,
in their effect on the responsiveness of virally infected
T cells to stimulation. HIV-1 Nef proteins may render
infected T cells hyper-responsive to stimulation and
promote the induction of cellular transcription factors,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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contrast, most primate lentiviral Nefs block T cell activa-
tion by down-modulation of TCR-CD3 and CD28 from
the cell surface [10]. These latter Nef functions are highly
conserved in sooty mangabeys that are naturally infected
with SIVsmm [11] and may play a protective role in vivo
since efficient modulation of TCR-CD3 and CD28 corre-
lates with high and stable CD4+ T cell counts in natural
SIVsmm infection [12] and in viremic HIV-2-infected
individuals [13].
To examine their functional properties, we PCR-amplified
nef genes from three previously described HIV-1-infected
VNPs from the Amsterdam Cohort Studies on HIV in-
fection and AIDS [3] obtained after six to 14 years of
documented HIV-1 infection. For comparison, we utilized
nef alleles amplified from plasma samples obtained from
eight individuals with progressing HIV-1 infection (P) and
seven previously characterized HIV-1, HIV-2, SIVmac
and SIVsmm nef alleles (Additional file 1: Table S1). It has
previously been shown that SIV Nefs modulate variousNL4-3 MGGKWSKSSV IGWPAVRERM RRAEPAA--- -----D---- GVGAVSR
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Figure 1 Amino acid alignment of VNP- and P-Nef proteins. Nef alleles
in Nef, including the N-terminal myristoylation signal, the M20 and WL residue
proline-rich and diarginine motifs, a thioesterase binding site, a C-proximal ad
are indicated. Residues 22 and 62 are highlighted yellow. Dots specify identity
optimize the alignment.receptors and enhance viral infectivity and replication
in a species-independent manner [10,14]. Between four
and ten nef alleles were sequenced per VNP and P sam-
ple and those predicting amino acid sequences that
were identical or almost identical to the respective pa-
tient and time point-specific consensus sequence and
thus most representative were selected for further ana-
lysis (Figure 1). All nef alleles encoded and expressed
full-length proteins (Additional file 1: Figures S1) and
previously defined functional domains were conserved
(Figure 1), suggesting that Nef proteins from both
groups of HIV-1-infected individuals are functionally
active. No specific sequence signatures were observed
in VNP-Nefs, although they frequently contained 22Q
(9/11) and 62T (9/11), whereas those from progressing
individuals contained 22R (5/8) and 62A (6/8; num-
bers indicate positions in the Nef alignment shown in
Figure 1). Given the different cohorts from which the
VNP and P samples originated, these are likely to be
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CD4 Acidic P(xxP)3
from VNPs and Ps are compared. Some conserved sequence elements
s (involved in MHC-I or CD4 down-modulation, respectively), the acidic,
aptor-protein (AP) interaction site and a diacidic putative V1H binding site
with the NL4-3 Nef sequence; dashes indicate gaps introduced to
Heigele et al. Retrovirology 2014, 11:13 Page 3 of 7
http://www.retrovirology.com/content/11/1/13For functional analyses all nef alleles shown in Figure 1
were cloned into an HIV-1 NL4-3 proviral construct that
co-expresses Nef and eGFP via an internal ribosomal
entry site [14]. Viral particles were generated by co-
transfection of 293T cells with the HIV-1 nef-IRES-eGFP
proviral constructs and a plasmid (pHIT-G) expressing
the vesicular stomatitis virus G glycoprotein and used
for transduction of peripheral blood mononuclear cells
(PBMCs) or CD4+ T cells as previously described [10,12].
Flow cytometric analyses performed at two days post-
transduction showed that nef alleles from both VNPs
and Ps down-modulated CD4 and (to a lesser extent)
MHC-I and CD28 from the cell surface (Figures 2A-C
and Additional file 1: Figure S2). VNP and P Nefs did
not show significant differences in receptor modulation
but were significantly less active in down-modulating
CD28 than HIV-2 and SIV Nefs (Co2) (Figure 2C).
Moreover, none of the patient-derived and control HIV-1
Nefs was capable of down-modulating TCR-CD3, whereas
HIV-2 and SIV Nefs were highly effective (Figure 2D).
In addition to reducing the lysis of HIV-1-infected cells
by cytotoxic T lymphocytes (CTL) by removing MHC-I
from the cell surface, Nef is also able to impair CTL
function directly by down-modulation of CD8β [15,16].
Analyses performed in CEM cells stably expressing







































































Figure 2 No group-specific difference of Nef-mediated regulation of s
analysis of Nef-mediated modulation of (A) CD4 and (B) MHC-I in primary
A2-CD8β fusion cells and (F) CD74 (Ii) in THP-1 cells transduced with HIV-1
patient-derived nef alleles. A vpu and env defective HIV-1 backbone was us
n-fold modulation of cell surface expression compared to the nef-defective
three independent experiments. Nef alleles were derived from the HIV-1 NL4-
HIV-2 60415 K, SIVsmm FWr1 and FFm1 Nefs (Co2, blue), VNPs (n = 11, green)modulation is conserved between nef alleles derived
from both groups of HIV-1-infected individuals (Figures 2E
and Additional file 1: FigureS2). Unexpectedly, HIV-2,
SIVsmm and SIVmac Nefs that all belong to the same
lineage of primate lentiviruses were significantly more
active than the HIV-1 control Nefs (Figure 2E). Nef may
also impair MHC-II-dependent antigen-presentation by
up-regulating surface expression of the invariant chain
(CD74) [17,18]. Potentially, inefficient activation of T
cells by antigen-presenting cells (APCs) due to potent
up-modulation of CD74 may reduce the levels of immune
activation. We found, however, that VNP- and P-Nefs did
not differ significantly in their ability to enhance CD74 cell
surface expression in infected THP-1 cells (Figure 2F).
Up-modulation of CD74 was reduced for nef alleles ob-
tained later during infection of VNPs 68 and 337, whereas
the ability of VNP-Nefs to modulate other receptors did
not change significantly throughout the course of infection
(Additional file 1: Figure S3). Whether or not the ability
of Nef to suppress MHC-II antigen presentation by up-
regulation of CD74 may be modulated throughout the
course of HIV-1 infection and if this Nef function plays
a role in the pathogenesis of AIDS remains to be analyzed
in larger patient cohorts.
The above mentioned results demonstrated that the





































urface receptors. (A-F) Quantitative assessment of flow cytometric
CD4+ T cells, (C) CD28 and (D) TCR-CD3 in PBMCs, (E) CD8β in CEM
recombinants expressing eGFP alone (nef-) or together with control or
ed to measure the effect of Nef on CD4 surface expression. Given are
control HIV-1 construct (average values ± standard errors) derived from
3, NA7 and JR-CSF molecular clones (Co1, black); SIVmac239, HIV-2 BEN,
and Ps (n = 8, red). Co, control; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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receptors involved in the activation of T cells by APCs.
It is known, however, that the HIV-1 Nef may also affect
T cell activation by modulating downstream signaling
pathways [19,20]. To directly examine the effects of Nef
on the responsiveness of primary human cells to activa-
tion, we infected PBMCs with various HIV-1 IRES/eGFP
constructs and stimulated them by PHA treatment as
described previously [10]. The results showed that virally
infected cells expressing VNP- and P-Nefs expressed higher
surface levels of CD69 and CD25 than cells producing
HIV-2 or SIV Nefs (Figure 3A, B). Expression of the early
and late T cell activation markers correlated with one
another (Figure 3C) and inversely with the efficiency of
Nef-mediated modulation of CD28 (Figure 3D). Similarly,
the levels of apoptosis were higher in HIV-1-infectedFigure 3 VNP-Nefs cannot prevent activation-induced apoptosis of in
two days, respectively, after the second PHA stimulation in PBMCs transduc
Nefs. (C, D) Correlations between expression of CD25 and (C) CD69 or (D)
levels of apoptosis two days post-stimulation in HIV-1-infected PBMCs. (F-H) C
or (H) CD28 down-modulation by the respective Nefs. (I) PHA-induced NF-AT
transfected with an NF-AT-dependent reporter gene [9]. (J) Correlation betwe
(K) Nef-mediated activation of NF-κB in 293Ts co-transfected with a NF-κB-de
construct and an expression vector expressing the various Nef proteins in the
Panels A, B, E, I and K give average values (±SD) relative to those obtained wit
independent experiments. Refer to the legend to Figure 2 for abbreviations, sPBMCs expressing VNP- and P-Nefs, compared to those
expressing SIV or HIV-2 Nefs (Figure 3E) and correlated
directly with the expression of T cell activation markers
and inversely (albeit imperfectly) with CD28 cell surface
expression (Figure 3F-H). These results are in agreement
with previous studies showing that Nef-mediated down-
modulation of TCR-CD3 and (to a lesser extent) CD28
suppresses the responsiveness of virally infected T cells to
stimulation and activation-induced cell death [10,12,13].
It has been reported that HIV-1 Nef may increase acti-
vation of the nuclear factors of activated T cells and kappa
B (NF-AT and NF-κB), respectively [9]. Both of these tran-
scription factors play key roles in innate immunity and
inflammatory responses [22,23] and may thus affect the
levels of infection-associated immune activation. Mea-
surements of the impact of Nef on NF-AT-dependentfected cells. (A, B) Expression of (A) CD69 and (B) CD25 at one or
ed with HIV-1 IRES/eGFP constructs expressing the indicated groups of
Nef-mediated CD28 down-modulation. (E) Quantitative assessment of
orrelation between apoptosis and expression of (F) CD69 and (G) CD25
-dependent luciferase activity in HIV-1 infected Jurkat cells stably
en CD69 expression and NF-AT-dependent luciferase expression.
pendent firefly luciferase construct, a pTAL promoter gaussia luciferase
presence of TNFα. The assay was performed as described elsewhere [21].
h the nef-defective control HIV-1 construct and were derived from three
ymbols, color coding and nef alleles analyzed.
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http://www.retrovirology.com/content/11/1/13luciferase expression in stably transfected Jurkat T cells
[9] showed that HIV-1 Nefs were generally associated
with higher levels of NF-AT activation than HIV-2 and
SIV Nefs (Figure 3I, J). While this was expected from
























































































































Figure 4 VNP Nefs enhance virion infectivity and viral replication. (A)
HIV-1 IRES-EGFP constructs expressing the indicated groups of nef alleles. Infe
panels give average values ± SD. RLU, relative light units. (B) Average levels of
of culture. PBMCs were either stimulated with PHA (1 μg/ml) for 3 days prior t
thereof [28] or infected immediately after isolation and stimulated three days
HIV-1 infection was assessed by measuring p24 antigen content. The values w
production in human lymphoid tissue (HLT) infected ex vivo. (E) Depletion of
infected with X4 HIV-1 NL4-3 expressing the indicated nef alleles, and cum
CD4+ T-cell depletion at the end of culture was determined as described
symbols, color coding and nef alleles analyzed.suppressed NF-AT activation more efficiently than VNP-
Nefs. In contrast, P-Nefs trended towards association
with higher levels of NF-κB activation than VNP-Nefs,
although this difference failed to reach significance






















P4-CCR5 (left) and TZM-bl (right) cells were infected with recombinant
ctions were performed in triplicate with two independent virus stocks. All
p24 antigen and (C) cumulative p24 production by PBMCs over 11 days
o infection with the X4-tropic HIV-1 NL4-3 clone or an R5-tropic derivative
later. Supernatants were collected at 2- or 3-day intervals, and productive
ere derived from three independent experiments. (D) Cumulative virus
CD4+ T cells in HLT infected ex vivo. Tissues from six donors were
ulative p24 production by the tissue blocks over 15 days or
previously [25,27]. Refer to the legend to Figure 2 for abbreviations,
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were associated with higher levels of CD69 (p = 0.0013)
and CD25 (p = 0.0012) expression, apoptosis (p = 0.0002)
and NF-AT activation (p = 0.0111) than primary patient-
derived nef genes (Figure 3). It is also noteworthy that
HIV-2 and SIV Nefs efficiently suppressed induction of
NF-AT but were particularly active in stimulating NF-κB
(Figure 3I, K). Thus, these primate lentiviruses may effi-
ciently activate the viral LTR via its NF-κB containing core
enhancer element but avoid NF-AT dependent induction
of immune response genes.
Finally, we examined the ability of VNP-Nefs to enhance
HIV-1 infection, replication and cytopathicity. Infection
of P4-CCR5 and TZM-bl indicator cells [24] with virus
stocks containing normalized quantities of p24 antigen
derived from 293T cells transiently transfected with the
different proviral constructs [24], showed that most VNP-
and P-Nefs enhanced virion infectivity, albeit with variable
efficacy (Figure 4A, Additional file 1: Figure S3). In agree-
ment with published data [25] the magnitude of the Nef
effect on HIV-1 infection was much higher in P4-CCR5
cells than in TZM-bl cells that are highly susceptible to
infection. To determine the effect of Nef on HIV-1 rep-
lication in primary human cells, PBMCs were infected
with HIV-1 constructs and virus production in the super-
natant was determined as described previously [26]. In
agreement with the high viral loads, VNP-Nefs in-
creased virus production (Figure 4B), irrespectively of
the viral coreceptor tropism, and of whether or not the
PBMCs were pre-stimulated or stimulated 3 days after
infection (Figure 4C). Since PBMC cultures may not
faithfully recapitulate the viral phenotype in vivo, we also
determined the levels of viral replication and CD4+ T
cell depletion in ex vivo human tonsillary tissues that
allow determination of the cytopathicity and replication
capacity of HIV-1 without exogenous stimulation [27].
Since the number of cultures that could be set up per
tonsil was limited, we only compared the effect of the
VNP-Nefs with the HIV-1 control Nefs. We found that
HIV-1 constructs expressing VNP-Nefs replicated effi-
ciently in human lymphoid tissue (HLT) and depleted
CD4+ T cells as effectively as otherwise isogenic viral
strains expressing the control NL4-3 and NA7 Nefs
(Figure 4D, E). These results are in agreement with the
previous finding that biologically cloned HIV-1 isolates
from these three VNPs are cytopathic and replication
competent in ex vivo infected human lymphoid tissue [3].
In conclusion, low levels of chronic inflammation and
lack of disease progression in VNPs are not due to effi-
cient Nef-mediated suppression of T cell activation. The
possible relevance and significance of the modest differ-
ences in modulation of NF-AT and NF-κB by VNP- and
P-Nefs observed in the present study needs to be further
examined in larger patient cohorts. Notably, our datasuggest that nef alleles derived from primary HIV-1
strains but not those of T cell line adapted molecular
clones of HIV-1 may suppress T cell activation, albeit
much less efficiently than HIV-2 and SIV nef genes that
down-modulate TCR-CD3. Thus, our results further
underline the necessity to use primary nef alleles to
avoid in vitro artifacts. Finally, our findings suggest that
host factors rather than specific viral properties may
allow VNPs to avoid harmful chronic immune activation
by HIV-1 replication.
Additional file
Additional file 1: Overview on nef alleles analyzed. Figure S1.
Expression of Nef proteins. Western blot analysis of lysates from 293T cells
transfected with pCGCG vectors expressing AU-1-tagged versions of the
indicated Nef proteins. Lysates were probed with an anti AU-1 monoclonal
antibody (Covance), anti β-actin polyclonal antibody (Abcam) and anti GFP
polyclonal antibody (Abcam). Figure S2. Modulation of various receptors by
VNP- and P-Nefs. Primary CD4+ T cells were transduced with NL4-3 con-
structs coexpressing the indicated nef alleles and GFP and assayed by FACS.
CEM cells expressing A2-CD8β fusions and THP-1 cells were utilized to
examine modulation of CD8ß and CD74 expression, respectively. The ranges
of eGFP expression used to calculate receptor modulation in Figure 1 are
indicated. Figure S3. Activity of VNP-Nefs throughout the course of infection.
(A-F) Quantitative assessment of Nef-mediated modulation of (A) CD4, (B)
MHC-I, (C) CD28 and (D) TCR-CD3 in primary cells, (E) CD8β in CEM A2-CD8β
fusion cells and (F) CD74 (Ii) in THP-1 cells transduced with HIV-1 recombi-
nants expressing eGFP alone (nef-) or together with various nef alleles. (G to I)
Quantitative analysis of (G) CD69 expression, (H) CD25 expression or (I)
apoptosis levels in transduced PBMCs. (J) PHA-induced NF-AT-dependent
luciferase activity obtained from transduced Jurkat cells stably transfected
with an NF-AT-dependent reporter gene. (K) Analysis of Nef-mediated
activation of NF-κB in 293Ts co-transfected with a NF-κB-dependent firefly
luciferase construct, a pTAL promoter gaussia luciferase construct (to
normalize) and Nef expression vectors in the presence of TNFα. (L)
Nef-mediated enhancement of infectivity in P4-CCR5 cells. Given are average
values ±SEM derived from multiple experiments of Nefs from HIV-1 NA7
(white), HIV-2 BEN (blue), VNP 68 (light green), VNP 337 (middle green) and
VNP 750 (dark green). Numbers below bars provide month of sampling after
the estimated data of primary infection.
Competing interests
The authors declare no conflict of interest.
Authors’ contributions
AH performed most experiments. DC and AvW contributed reagents. AH and
FK designed the study, performed the statistical analysis, and wrote the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Kerstin Regensburger, Martha Meyer, Birgit Ott and
Daniela Krnavek for excellent technical assistance, Dre van der Merwe and
Daniel Sauter for critical reading, and Heinz Maier from the Military Hospital
Ulm and Thomas Hoffmann from the Department of Ear-Nose and Throat,
Ulm University Medical Center for providing tonsillary tissues. Further we thank
Bernd Baumann, University Ulm for providing the NF-κB firefly luciferase reporter
plasmid. HIV-infected progressor (P) samples were sampled from the
BRESCIA cohorts and kindly provided by Carlo Torti. This work was
supported by the Deutsche Forschungsgemeinschaft (DFG) and the
European Research Council (ERC).
The Amsterdam Cohort Studies on HIV infection and AIDS, a collaboration
between the Amsterdam Health Service, the Academic Medical Center of the
University of Amsterdam, Sanquin Blood Supply Foundation, the University
Medical Center Utrecht, and the Jan van Goyen Clinic are part of the
Netherlands HIV Monitoring Foundation and financially supported by the
Heigele et al. Retrovirology 2014, 11:13 Page 7 of 7
http://www.retrovirology.com/content/11/1/13Center for Infectious Disease Control of the Netherlands National Institute for
Public Health and the Environment. All experiments reported in this study
and bllod sampling were performed with the approval of the local ethics
committees. We are indebted to all participants for their continuous
participation in the study.
Author details
1Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
2Cancer Research Institute, Institute for Immunology, Center for Virus Research,
University of California Irvine, Irvine, California, USA. 3Department of
Experimental Immunology, Sanquin Research, Landsteiner Laboratory and
Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical
Center of the University of Amsterdam, Amsterdam, The Netherlands. 4Present
address: Crucell Holland BV, Leiden, The Netherlands.
Received: 1 October 2013 Accepted: 26 January 2014
Published: 4 February 2014References
1. Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, Else JG, Estes JD,
Hahn BH, Hirsch VM, Kaur A, Kirchhoff F, Muller-Trutwin M, Pandrea I,
Schmitz JE, Silvestri G: Toward an AIDS vaccine: lessons from natural
simian immunodeficiency virus infections of African nonhuman primate
hosts. Nat Med 2009, 15:861–865.
2. Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G: Natural
SIV hosts: showing AIDS the door. Science 2012, 335:1188–1193.
3. Choudhary SK, Vrisekoop N, Jansen CA, Otto SA, Schuitemaker H, Miedema F,
Camerini D: Low immune activation despite high levels of pathogenic
human immunodeficiency virus type 1 results in long-term asymptomatic
disease. J Virol 2007, 81:8838–8842.
4. Kirchhoff F: Role of Nef in primate lentiviral immunopathogenesis.
Cell Mol Life Sci 2008, 65:2621–2636.
5. Arien KK, Verhasselt B: HIV Nef: role in pathogenesis and viral fitness.
Curr HIV Res 2008, 6:200–208.
6. Skowronski J, Parks D, Mariani R: Altered T cell activation and
development in transgenic mice expressing the HIV-1 nef gene.
EMBO 1993, 12:703–713.
7. Wang JK, Kiyokawa E, Verdin E, Trono D: The Nef protein of HIV-1
associates with rafts and primes T cells for activation. Proc Natl Acad Sci
USA 2000, 97:394–399.
8. Fenard D, Yonemoto W, de Noronha C, Cavrois M, Williams SA, Greene WC:
Nef is physically recruited into the immunological synapse and
potentiates T cell activation early after TCR engagement. J Immunol 2005,
175:6050–6057.
9. Fortin JF, Barat C, Beauséjour Y, Barbeau B, Tremblay MJ: Hyper-responsiveness
to stimulation of human immunodeficiency virus-infected CD4+ T cells
requires Nef and Tat virus gene products and results from higher NFAT,
NF-kappaB, and AP-1 induction. J Biol Chem 2004, 279:39520–39531.
10. Schindler M, Münch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F,
Müller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques
R, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F: Nef-mediated
suppression of T cell activation was lost in a lentiviral lineage that gave
rise to HIV-1. Cell 2006, 125:1055–1067.
11. Schmökel J, Li H, Bailes E, Schindler M, Silvestri G, Hahn BH, Apetrei C,
Kirchhoff F: Conservation of Nef function across highly diverse lineages
of SIVsmm. Retrovirology 2009, 6:36.
12. Schindler M, Schmökel J, Specht A, Li H, Münch J, Khalid M, Sodora DL,
Hahn BH, Silvestri G, Kirchhoff F: Inefficient Nef-mediated downmodulation
of CD3 and MHC-I correlates with loss of CD4 + T cells in natural SIV
infection. PLoS Pathog 2008, 4:e1000107.
13. Khalid M, Yu H, Sauter D, Usmani SM, Schmökel J, Feldman J, Gruters RA,
van der Ende ME, Geyer M, Rowland-Jones S, Osterhaus AD, Kirchhoff F:
Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is
associated with high CD4+ T cell counts in viremic HIV-2 infection. J Virol
2012, 86:4906–4920.
14. Münch J, Rajan D, Schindler M, Specht A, Rücker E, Novembre FJ, Nerrienet E,
Müller-Trutwin MC, Peeters M, Hahn BH, Kirchhoff F: Nef-mediated
enhancement of virion infectivity and stimulation of viral replication are
fundamental properties of primate lentiviruses. J Virol 2007, 81:13852–13864.15. Leonard JA, Filzen T, Carter CC, Schaefer M, Collins KL: HIV-1 Nef disrupts
intracellular trafficking of MHC-I, CD4, CD8, and CD28 by distinct path-
ways that share common elements. J Virol 2011, 85:6867–6881.
16. Heigele A, Schindler M, Gnanadurai CW, Leonard JA, Collins KL, Kirchhoff F:
Down-modulation of CD8αβ is a fundamental activity of primate
lentiviral Nef proteins. J Virol 2012, 86:36–48.
17. Stumptner-Cuvelette P, Morchoisne S, Dugast M, Le Gall S, Raposo G, Schwartz O,
Benaroch P: HIV-1 Nef impairs MHC class II antigen presentation and surface
expression. Proc Natl Acad Sci U S A 2001, 98:12144–12149.
18. Schindler M, Wildum S, Casartelli N, Doria M, Kirchhoff F: Nef alleles from
children with non-progressive HIV-1 infection modulate MHC-II expression
more efficiently than those from rapid progressors. AIDS 2007, 21:1103–1107.
19. Renkema GH, Saksela K: Interactions of HIV-1 Nef with cellular signal
transducing proteins. Front Biosci 2000, 5:D268–D283.
20. Greenway AL, Holloway G, McPhee DA, Ellis P, Cornall A, Lidman M: HIV-1
nef control of cell signaling molecules: multiple strategies to promote
virus replication. J Biosci 2003, 28:323–335.
21. Hotter D, Kirchhoff F, Sauter D: HIV-1 Vpu does not degrade interferon
regulatory factor 3. J Virol 2013, 87:7160–7165.
22. Fric J, Zelante T, Wong AY, Mertes A, Yu HB, Ricciardi-Castagnoli P: NFAT
control of innate immunity. Blood 2012, 120:1380–1389.
23. Pitha PM: Innate antiviral response: role in HIV-1 infection. Viruses 2011,
3:1179–1203.
24. Charneau PG, Mirambeau P, Roux P, Paulous S, Buc H, Clavel F: HIV-1 reverse
transcription. A termination step at the center of the genome. J Mol Biol
1994, 241:651–662.
25. Schindler M, Rajan D, Specht A, Ritter C, Pulkkinen K, Saksela K, Kirchhoff F:
Association of Nef with p21-activated kinase 2 is dispensable for efficient
human immunodeficiency virus type 1 replication and cytopathicity in
ex vivo-infected human lymphoid tissue. J Virol 2007, 81:13005–13014.
26. Specht A, Telenti A, Martinez R, Fellay J, Bailes E, Evans DT, Carrington M,
Hahn BH, Goldstein DB, Kirchhoff F: Counteraction of HLA-C-mediated
immune control of HIV-1 by Nef. J Virol 2010, 84:7300–7311.
27. Glushakova S, Grivel JC, Suryanarayana K, Meylan P, Lifson JD, Desrosiers R,
Margolis L: Nef enhances human immunodeficiency virus replication and
responsiveness to interleukin-2 in human lymphoid tissue ex vivo. J Virol
1999, 73:3968–3974.
28. Papkalla A, Münch J, Otto C, Kirchhoff F: Nef enhances human
immunodeficiency virus type 1 infectivity and replication independently
of viral coreceptor tropism. J Virol 2002, 76:8455–8459.
doi:10.1186/1742-4690-11-13
Cite this article as: Heigele et al.: Viremic long-term nonprogressive HIV-1
infection is not associated with abnormalities in known Nef functions. Ret-
rovirology 2014 11:13.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
